Attached files
file | filename |
---|---|
EX-10.1 - EX-10.1 - QUESTCOR PHARMACEUTICALS INC | a57412exv10w1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 27, 2010
QUESTCOR PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
California | 001-14758 | 33-0476164 | ||
(State or Other Jurisdiction | (Commission File Number) | (I.R.S. Employer | ||
of Incorporation) | Identification No.) |
1300 North Kellogg Drive, Anaheim, California | 92807 | |||
(Address of Principal Executive Offices) | (Zip Code) |
Registrants
telephone number, including area code: (714) 820-4500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.01 Entry into a Material Definitive Agreement.
On September 27, 2010, Questcor Pharmaceuticals, Inc. (Questcor) entered into a transition
agreement (the Transition Agreement) with Gary Sawka, Questcors Senior Vice President and Chief
Financial Officer. Mr. Sawka has separately served on the board of directors of CAI International,
Inc. (CAP). Mr. Sawka has agreed to serve as interim Chief Financial Officer of CAP.
Effective October 1, 2010, Mr. Sawka transitions to part-time employment with Questcor until
December 31, 2010. The Transition Agreement provides compensation during that period of $5,579 per
month and continuation of certain benefits. The Transition Agreement also provides that Mr. Sawka
shall receive $70,000 following the transition period. The description of the Transition Agreement
does not purport to be complete and is qualified in its entirety by reference to the copy of the
Transition Agreement attached hereto as Exhibit 10.1 and incorporated herein by reference.
Item 1.02 Termination of a Material Definitive Agreement.
Effective October 1, 2010, Mr. Sawkas Severance Agreement, entered into by and between
Questcor and Mr. Sawka on September 10, 2008, will be terminated by mutual consent of the parties.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain Officers.
(b) The information contained in Item 1.01 of this Current Report on Form 8-K is incorporated
by reference herein.
(c) Questcor has appointed Kristine Engelke, CPA, as its Principal Accounting Officer,
effective October 1, 2010. Mrs. Engelke, 40, joined Questcor in August 2010 as its Corporate
Controller. From June 2001 to August 2010, Mrs. Engelke served as the Director of Finance/Corporate
Controller of ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA). From January 1998 to June 2001, Mrs.
Engelke served as a Corporate Controller for RBF Consulting, a privately held civil engineering
firm. From 1992 to 1997, Mrs. Engelke worked as an audit manager for Deloitte & Touche. Mrs.
Engelke has a B.S. in Economics with an emphasis in Accounting from the University of California,
Santa Barbara.
Item 8.01 Other Events.
Questcor has moved its corporate headquarters, including its Chief Executive Officer and its
finance function, to Anaheim, California. Commercial, marketing and manufacturing operations will
continue to be based in Union City, California. In connection with relocating its corporate
headquarters, Questcor has established a new finance team and is in the process of evaluating new
Chief Financial Officer candidates.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. | Description | |||
10.1 | Transition Agreement, by and between Gary Sawka and Questcor
Pharmaceuticals, Inc., dated September 27, 2010. |
SIGNATURES
Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report
to be signed on its behalf by the undersigned hereunto duly authorized.
Date: September 30, 2010 | QUESTCOR PHARMACEUTICALS, INC. |
|||
By: | /s/ Don M. Bailey | |||
Don M. Bailey | ||||
President and Chief Executive Officer | ||||
EXHIBIT INDEX
Exhibit No. | Description | |
10.1
|
Transition Agreement, by and between Gary Sawka and Questcor Pharmaceuticals, Inc., dated September 27, 2010. |